Abstract
The symptoms of narcolepsy can occur during the course of other neurologic conditions (ie, symptomatic narcolepsy). Inherited disorders, tumors, and head trauma were the three most frequent causes for symptomatic narcolepsy. Other causes include multiple sclerosis (MS), vascular disorders, and encephalitis. Cerebrospinal fluid hypocretin-1 measures were carried out in some recent cases with symptomatic narcolepsy, and moderate decreases in hypocretin levels were seen in a large majority of these cases. Excessive daytime sleepiness (EDS) in these symptomatic cases was sometimes reversible with an improvement of the causative neurologic disorder and with an improvement of the hypocretin (orexin) status. Recently, we found that several symptomatic narcoleptic cases with MS show unique bilateral symmetric hypothalamic lesions associated with significant hypocretin ligand deficiency. In addition, these patients often share the clinical characteristics of neuromyelitis optica (NMO) and the detection of NMO-IgG (or anti-aquaporin-4 [AQP4] antibodies), suggesting a new clinical entity. Further studies of the involvement of the hypocretin system in symptomatic narcolepsy and EDS are helpful to understand the pathophysiologic mechanisms for occurrence of EDS and cataplexy.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Nishino S, Kanbayashi T: Symptomatic narcolepsy, cataplexy, and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005, 9:269–310.
Ritchie C, Okuro M, Kanbayashi T, et al.: Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights. Curr Neurol Neurosci Rep. 2010 May;10(3):180–9.
Verma A, Anand V, Verma NP: Sleep disorders in chronic traumatic brain injury. J Clin Sleep Med 2007, 3:357–362.
von Economo C: Encephalitis lethargica: its sequelae and treatment 1931.
von Economo C: Sleep as a problem of localization. J Nerv Ment Dis 1930;71(3):249–59.
Mamelak M: A perspective on narcolepsy. Encephale 1992; 18(4):347–51.
Siegel J: Brainstem mechanisms generating REM sleep. In: Kryger MR, Roth T, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia, PA: W.B. Saunders; 2000. p. 112–33.
Aldrich M, Naylor M: Narcolepsy associated with lesions of the diencephalon. Neurology 1989;39(11):1505–8.
Nishino S, Ripley B, Overeem S, et al.: Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39–40.
Peyron C, Faraco J, Rogers W, et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991–997.
Thannickal T, Moore R, Nienhuis R, et al.: Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27(3):469–74.
Scammell T, Nishino S, Mignot E, Saper C: Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology 2001;56(12):1751–3.
Marcus C, Mignot E: Letter to the editor regarding our previous publication: Secondary narcolepsy in children with brain tumors. Sleep 2002;25:435–9.
Nishino S, Kanbayashi T, Fujiki N, et al.: CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. Neurology 2003, 61:823–825.
Overeem S, Dalmau J, Bataller L, et al.: Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 2004;62(1):138–40.
• Kanbayashi T, Shimohata T, Nakashima I, et al.: Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 2009, 66(12):1563–1566. The authors report a significant recent study of symptomatic narcolepsy in patients diagnosed with immune-mediated neurologic condition MS with bilateral hypothalamic inflammatory lesions. The findings specifically link the presence of anti-AQP4 antibody and the probability of immune attack in hypothalamic periventricular regions to reduced CSF hypocretin-1 levels. Further, they suggest that additional antibody-mediated mechanisms also contribute to secondary hypocretin system impairment, manifesting in EDS symptoms.
Poirier G, Montplaisir J, Dumont M, et al.: Clinical and sleep laboratory study of narcoleptic symptoms in multiple sclerosis. Neurology 1987;37(4):693–5.
Ripley B, Fujiki N, Okura M, et al.: CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253–2258.
Tachibana N, Howar RS, Hirsch NP, et al.: Sleep problems in multiple sclerosis. Eur Neurol 1994, 34:320–323.
Amiry-Moghaddam M, Ottersen, OP: The molecular basis of water transport in the brain. Nat Rev Neurosci 2003, 4:991–1001.
Pittock SJ, Weinshenker BG, Lucchinetti CF, et al.: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006 Jul;63(7):964–8.
Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473–477.
Nokura K, Kanbayashi T, Ozeki T, et al.: Hypersomnia secondary to hypothalamic damage and CSF Orexin-A level in four cases. Sleep 2004; 27(Suppl.):A249.
Tohyama J, Kanazawa O, Akasaka N, et al.: A case of bilateral paramedian thalamic infarction in childhood with the sensory disturbance and the sensory loss of taste. No To Hattatsu 2004;36(1):65–9.
Guilleminault C, Quera-Salva M, Goldberg M: Pseudohypersomnia and pre-sleep behaviour with bilateral paramedian thalamic lesions. Brain 1993;116(6):1549–63.
Bassetti C, Mathis J, Gugger M, et al.: Hypersomnia following paramedian thalamic stroke: a report of 12 patients. Ann Neurol 1996;39(4):471–80.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kanbayashi, T., Sagawa, Y., Takemura, F. et al. The Pathophysiologic Basis of Secondary Narcolepsy and Hypersomnia. Curr Neurol Neurosci Rep 11, 235–241 (2011). https://doi.org/10.1007/s11910-011-0178-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-011-0178-y